Last edition
News about "Advanced solid tumors"
Daiichi Sankyo Begins Clinical Development of CD25-Targeted ADC DS1025
Daiichi Sankyo advances DS1025 into clinical development as a potential first-in-class CD25-targeted Antibody Drug Conjugate (ADC) for patients with advanced solid tumors.
Advanced Solid Tumors | 01/09/2026 | By News Bureau
Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954
Ranok Therapeutics has reported positive Phase 1a clinical data for investigational KRAS G12D inhibitor RNK08954, demonstrating encouraging response rates and tolerability in advanced solid tumor patients, including those with non-small cell lung cancer.
Advanced Solid Tumors | 12/05/2026 | By News Bureau | 370
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy